Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- HSV vaccine development: challenges
- Herpes simplex virus illnesses
- Mucocutaneous HSV pathogenesis
- A few points about genital herpes (GH)
- Studies to be discussed
- Models for studying genital herpes
- Guinea pig model of HSV genital infection
- HSV-2 glycoprotein D subunit vaccine
- Effect of HSV-2 gD/AS04 vaccine: replication
- Effect of HSV-2 gD/AS04 vaccine: recurrence
- Prophylactic HSV-2 gD/AS04 immunization
- Guinea pig study: conclusions and questions
- Do vaccines prevent infection or disease? (1)
- Results of traditionally designed animal studies
- Animal studies using a range of virus doses
- Do vaccines prevent infection or disease? (2)
- Clinical studies
- HSV-2 vaccine phase III trials: Chiron vaccine
- HSV-2 vaccine phase III trials: GSK vaccine
- HSV-2 vaccine phase III trials: Herpevac study
- Gender effect against HSV-2 acquisition: GSK
- Gender effect against HSV-2 acquisition: Chiron
- Gender effect against HSV-2 acquisition
- Effect of pre-existing HSV-1 immunity
- Efficacy of Chiron gB2gD2-MF59 vaccine (1)
- Effect of pre-existing HSV-1 immunity: conclusion
- Are discordant couples a poor population? (1)
- Efficacy of Chiron gB2gD2-MF59 vaccine (2)
- Are discordant couples a poor population? (2)
- What about HSV-1 genital herpes?
- gD2-AS04 vaccine protection for healthy women
- What (I think) we know
- What (I think) we do not know (1)
- What (I think) we do not know (2)
- Discussion: burden of disease
- Developing a prophylactic HSV-2 vaccine (1)
- Developing a prophylactic HSV-2 vaccine (2)
- Therapeutic vaccine
- Acknowledgments
Topics Covered
- HSV vaccine development
- Herpes simplex virus illnesses
- Mucocutaneous HSV pathogenesis
- Genital herpes
- HSV-2 glycoprotein D subunit vaccine
- HSV-2 vaccine phase III trials: Chiron vaccine
- GSK vaccine
- Herpevac study
- Gender effect against HSV-2 acquisition
- Effect of pre-existing HSV-1 immunity
- Discordant couples population
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Stanberry, L. (2015, June 30). Herpes simplex virus vaccines [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 12, 2024, from https://doi.org/10.69645/RDKA3360.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Lawrence Stanberry has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Vaccines
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I'm Professor
Lawrence Stanberry, chairman
of the Department of Pediatrics
at Columbia University in the city
of New York, United States.
I'm pleased to be with
you today to speak
on the topic of herpes
simplex virus vaccines
as part of the Henry
Stewart Talks series.
0:20
In the first slide, we discuss
the challenges to the development
of a herpes simplex virus vaccine.
First, the audience needs
to be aware of the fact
that there are two herpes simplex
viruses, HSV type 1 and HSV type 2.
These viruses commonly infect
mucosal surfaces such as the skin,
but they also spread
into nervous tissue,
and the disease pathogenesis largely
involves skin and nervous tissue.
Viremia, that is, the spread
of virus in the bloodstream,
is not an important
element in the pathogenesis
in an immuno-competent
host, that's an individual
whose immune system is intact.
Infection due to herpes simplex
results in a lifelong infection.
The initial infection
may be asymptomatic
or clinically apparent.
Recurrent infections are exceedingly
common, sometimes symptomatic,
sometimes asymptomatic.
And they occur despite the fact
host has made a full complement
of immune responses.
So one of the biggest challenges
to developing an effective herpes
vaccine is the recognition that
natural infection does not result
in lifelong immunity protecting
against recurrent disease,
raising the question of how
do we improve upon immunity
that does result from infection.